Clinical Trial Update: Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating the combination of selinexor and ruxolitinib for myelofibrosis; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Ruxolitinib (Jakafi) (ruxolitinib)
• Selinexor (Xpovio) (Selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Myelofibrosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING